EUCTR2007-001457-26-HU进行中（未招募）1 期
A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP,PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THESAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTSWITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Has provided written informed consent and is willing to comply with scheduled visits, treatment plan, radiographs, laboratory tests, and other trial procedures;
- •2. Is a female aged =40 years with a BMI =30 and <40 kg/m2;
- •3. In the past, has been diagnosed with knee OA and has had knee symptoms in the past year defined as:
- •Pain, aching or stiffness on most days of a month; and/or
- •Used a medication (other than potent opioids) for treatment of knee pain on most days of a month;
- •4. Has a current level of pain (outside of acute flare) in at least 1 knee characterized by a WOMAC Pain subscale score of between 6 and 12, inclusive (where the range of sub-scores is 0-20); Note: Pain must be characterized as a subject’s normal day-to-day pain while on standard of care medication and not the pain associated with an acute flare.
- •5. Has been on the same standard of care medication(s) for OA pain in the knee(s) for at least 3 months and on a stable dosing regimen for at least 4 weeks preceding the first dose of study medication (stable defined as: Doses and frequency of administration remain unchanged);
- •6. Is of non-childbearing potential, if 1 of the 2 categories below is satisfied:
- •Is =45 years of age and amenorrheic for at least 2 years, or
- •Has proof of a physician documented hysterectomy and/or bilateral oophorectomy;
- •Note: Females not meeting the non-childbearing rules above or having undergone tubal ligation will be considered of childbearing potential for this study (refer to #7 next).
- •7. If of childbearing potential, has agreed that when sexually active, to use the protocoldesignated effective methods of contraception.
- •Central Imaging Core Laboratory Criteria for Inclusion
- •Subjects meeting the following Screen 1 inclusion criteria by radiography as assessed through the modified Lyon-schuss X-ray will be semi-qualified for Screen 2. Criteria 1-6 below will be assessed by the independent Central Reader and communicated back to the Central Imaging Core Laboratory, which will then assess the results against the OA history taken at the Screen 1 visit as the final step in determining which subjects will be invited back for Screen 2. A yes” answer to
- •each criteria is needed to continue screening.
- •1. A KLG 2 or 3 AND a medial tibiofemoral minimum JSW =2 mm in the study knee;
- •2. A KLG <4 in the contralateral knee;
- •3. An anatomic axis angle between 184 and 174 degrees inclusive in the study knee;
- •4. The lateral minimum joint space width (JSW) > the medial minimum JSW in the study knee;
- •5. No radiological findings such as, but not limited to avascular necrosis, fracture, infection, gout, Paget’s disease, osteopetrosis, osteochondritis, or other pathologies in the study knee.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects must meet all of the following Investigator Level inclusion criteria to advance to the knee imaging phase of Screen 1. Failure to meet these criteria will result in a Screen Fail for the subject
- •Subjects presenting with any of the following will not be eligible for knee imaging at the Radiology Center. A yes” response to any criterion below will result in a Screen Fail for the subject:
- •1. Subjects with a history of:
- •A diagnosis of any other rheumatic disease
- •Current, severe, uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, neurological disease, or any other condition which would make the subject unsuitable for the study within 6 months preceding the Screen 1 visit.
- •Clinically significant infections (acute infection or those requiring hospitalization or
- •An active malignancy of any type or history of a malignancy
- •Any known diseases or conditions that may involve the knees
- •Significant trauma to the knees (including arthroscopy or significant injury to ligaments or menisci of the knee within 1 year preceding the Screen 1 visit
- •2. Subjects presenting with:
- •A verified systolic blood pressure >150 mm Hg (if untreated for hypertension) or greater than 160 mm Hg (if treated for hypertension) and/or a diastolic blood pressure greater than 90 mm Hg;
- •An ECG finding considered by the Investigator to be clinically significant;
- •Any morbidities that would curtail work-related or leisure time physical activities such that these morbidities would contribute to increases in sedentary behaviors;
- •Chronic potent opioid use;
- •Any condition possibly affecting oral drug absorption;
- •Anticipated need for knee or hip surgery in the next 2 years;
- •Exacerbation of OA pain in either knee requiring a change in stable treatment within 4 weeks of the Screen 1 visit;
- •Symptomatic OA of either hip by history or elicited on physical examination that may
- •confound the interpretation of knee pain;
- •Clinically significant non-articular musculoskeletal pain that cannot be distinguished
- •from knee OA;
- •Intra-articular hyaluronic acid to either knee within 6 months preceding the Screen 1
- •Use of any investigational drug within 1 month preceding the Screen 1 visit;
- •3. Pregnant or breastfeeding females;
- •4. Anticipating a move out of the area of the clinic in the next 2 years.
- •5. A subject anticipating or participating in a defined weight loss program for any reason in the next 2 years.
- •Exclusion Criteria at Screen 2
- •Subjects advancing to Screen 2 will have successfully completed the cursory review of safety, have passed the Investigator Level inclusion/exclusion tests of Screen 1, and have been successfully screened by the Central Reader and the Central Imaging Core Laboratory. The Screen 2 visit will essentially complete all other safety screens for eligibility and establish the baseline values for safety and for the majority of secondary efficacy assessments.
- •Subjects presenting with any of the following will not qualify for randomization. Failure to meet these criteria will result in a Screen Fail for the subject:
- •1. Clinical signs of tuberculosis (TB) such as generalized tiredness or weakness, weight loss, fever, night sweats, coughing, chest pain, coughing up sputum and/or blood, shortness of breath, x-ray showing infiltrates or fibrosis suggestive of TB;
- •2. Currently undergoing treatment for TB;
- •3. Evidence of latent TB infection (LTBI) without documented evidence of treatment with an acceptable c
研究者
相似试验
进行中（未招募）
不适用
A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP,PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THESAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTSWITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEEOsteoarthritisEUCTR2007-001457-26-CZPfizer Inc, 235 East 42nd Street, New York, NY 100171,400
进行中（未招募）
不适用
A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTS WITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEE - NDOsteoarthritisEUCTR2007-001457-26-ITPFIZER1,400
已完成
不适用
A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTS WITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEE-M17M17PER-020-08PFIZER S.A.,111
进行中（未招募）
1 期
A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP,PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THESAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTSWITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEEESTUDIO RADIOGRÁFICO A LARGO PLAZO, ALEATORIZADO, DOBLE CIEGO, CON GRUPOS PARALELOS Y CONTROLADO CON PLACEBO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE SD-6010 ADMINISTRADO POR VÍA ORAL EN PACIENTES CON ARTROSIS SINTOMÁTICA DE RODILLAOsteoarthritisArtrosisMedDRA version: 9.1Level: LLTClassification code 10023476Term: Knee osteoarthritisEUCTR2007-001457-26-ESPfizer, S.A.1,400
进行中（未招募）
1 期
A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP,PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THESAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTSWITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEEMedDRA version: 9.1Level: LLTClassification code 10023476Term: Knee osteoarthritisOsteoarthritisEUCTR2007-001457-26-SKPfizer Inc, 235 East 42nd Street, New York, NY 100171,400